特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

軸性脊椎関節炎 (axSpA):アジア太平洋地域における疫学的予測

Axial Spondyloarthritis: Forecast in Asia-Pacific Markets to 2028

発行 GlobalData 商品コード 919453
出版日 ページ情報 英文 150 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
軸性脊椎関節炎 (axSpA):アジア太平洋地域における疫学的予測 Axial Spondyloarthritis: Forecast in Asia-Pacific Markets to 2028
出版日: 2020年02月28日 ページ情報: 英文 150 Pages
概要

アジア太平洋地域の主要国における、軸性脊椎関節炎 (axSpA) の受診済み有病者数は、2018年には610万人、2028年には800万人と、年率3.23%の速度で増加する見通しです。2018年の受診済み有病者数を国別に見ると、中国 (都市部) は310万人、インドが280万人、オーストラリアが8万人となっています。人口増加や高齢化の進展などが、有病者数の増加を促しています。

当レポートでは、アジア太平洋地域の主要5ヶ国 (オーストラリア、中国 (都市部)、インド、韓国、日本) における、体軸性脊椎関節炎 (axSpA) の発症状況と今後の見通しについて分析し、疾患の特徴や、現在の有病者の発症状況、今後10年間の有病件数・市場規模の見通し (基本的/代替的シナリオ)、疾患種類別・特性別の詳細動向、といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 軸性脊椎関節炎 (axSpA):エグゼクティブサマリー

  • 関連分析
  • 刊行予定の関連分析

第3章 疫学

  • 疾患の背景事情
  • リスク要因と共存症
  • 過去の世界的傾向
  • 予測手法
    • 情報源
    • 予測の前提条件と手法:強直性脊椎炎 (AS) の場合 - 基本的シナリオ
    • 予測の前提条件と手法:非レントゲン性軸性脊椎関節炎 (Nr-AxSpA) の場合 - 基本的シナリオ
    • 予測の前提条件と手法:強直性脊椎炎 (AS) の場合 - 代替的シナリオ
    • 予測の前提条件と手法:非レントゲン性軸性脊椎関節炎 (Nr-AxSpA) の場合 - 代替的シナリオ
    • 予測の前提条件と手法:診断済みAS患者のうち、HLA-B27陽性反応との関連性がある場合
  • AS/Nr-AsSpAの疫学的予測 (今後11年間分) - 基本シナリオ
    • ASの受診済み有病者数
    • Nr-AxSpAの受診済み有病者数
  • AS/Nr-AsSpAの疫学的予測 (今後11年間分) - 代替的シナリオ
    • ASの受診済み有病者数
    • ASの受診済み有病者数:年齢別
    • ASの受診済み有病者数:男女別
    • ASの受診済み有病者数:HLA-B27陽性の有無別
    • Nr-AxSpAの受診済み有病者数
    • Nr-AxSpAの受診済み有病者数:年齢別
    • Nr-AxSpAの受診済み有病者数:男女別
  • 議論
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

List of Tables

  • Table 1: Axial Spondyloarthritis: Key Metrics in the 5GM
  • Table 2: Risk Factors and Comorbidities for AS
  • Table 3: Treatment Guidelines for AxSpA
  • Table 4: Country Profile - India
  • Table 5: Country Profile - China
  • Table 6: Country Profile - Aus

List of Figures

  • Figure 1: Global Sales Forecast by Country for Axial Spondyloarthritis in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in Axial Spondyloarthritis During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of Axial Spondyloarthritis During the Forecast Period
  • Figure 4: Pathogenic Mechanisms of Axial Spondyloarthritis
  • Figure 5: 5GM, Diagnosed Prevalence (%) of AxSpA, Both Sexes, Ages ≥18 Years, 2008-2028 - Base Scenario
  • Figure 6: 5GM, Sources Used, Diagnosed Prevalent Cases of AS - Base Scenario
  • Figure 7: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-axSpA - Base Scenario
  • Figure 8: 5GM, Sources Used, Diagnosed Prevalent Cases of AS - Alternative Scenario
  • Figure 9: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-axSpA - Alternative Scenario
  • Figure 10: 5GM, Sources Used, HLA-B27 Seropositivity Data Among the Diagnosed Prevalent Cases of AS - Alternative Scenario
  • Figure 11: 5GM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 - Base Scenario
  • Figure 12: 5GM, Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, Both Sexes, N, 2018 - Base Scenario
  • Figure 13: 5GM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
  • Figure 14: 5GM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N, 2018 - Alternative Scenario
  • Figure 15: 5GM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ≥18 Years, N, 2018 - Alternative Scenario
  • Figure 16: 5GM, Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
  • Figure 17: 5GM, Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
  • Figure 18: 5GM, Age-Specific Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, N, 2018 - Alternative Scenario
  • Figure 19: 5GM, Sex-Specific Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, N, 2018 - Alternative Scenario
  • Figure 20: Flowchart of the Diagnosis and Management of Axial Spondyloarthritis
  • Figure 21: Unmet Needs and Opportunities in AxSpA
  • Figure 22: Overview of the Development Pipeline for AxSpA
  • Figure 23: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for AxSpA in the Five Growth Markets in Asia-Pacific During the Forecast Period
  • Figure 24: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of AxSpA in the Five Growth Markets in Asia-Pacific During the Forecast Period
  • Figure 25: Analysis of the Company Portfolio Gap in AxSpA in the 5GM, During the Forecast Period
  • Figure 26: APAC (5GM) Sales Forecast by Country for Axial Spondyloarthritis in 2018 and 2028
  • Figure 27: Sales Forecast by Class for Axial Spondyloarthritis in India in 2018 and 2028
  • Figure 28: Sales Forecast by Class for Axial Spondyloarthritis in China in 2018 and 2028
  • Figure 29: Sales Forecast by Class for Axial Spondyloarthritis in Australia in 2018 and 2028
  • Figure 30: Sales Forecast by Class for Axial Spondyloarthritis in South Korea in 2018 and 2028
  • Figure 31: Sales Forecast by Class for Axial Spondyloarthritis in Japan in 2018 and 2028
目次
Product Code: GDHC184PIDR

The diagnosed prevalent cases of Axial Spondyloarthritis (AxSpA) are expected to increase from 6.1 million cases in 2018 to 8.0 million cases in 2028, at an annual growth rate (AGR) of 3.23% across the five growth markets (5GM: Australia, China [urban], India, South Korea and Japan) in the Asia-Pacific (APAC) region.

Axial Spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Axial Spondyloarthritis (AxSpA) usually starts in the third decade of the life, and can have a major impact on patient health-related quality of life and work productivity.

Axial Spondyloarthritis (AxSpA) is an insidious disease and difficult to diagnose. Diagnosis is aided by family history, clinical examination, C-reactive protein (CRP), HLA-B27 testing and radiographic imaging. Diagnoses of Axial Spondyloarthritis (AxSpA) patients have an average delay of eight years from the onset of symptoms.

Of the 5GM (Australia, China [urban], India, South Korea and Japan), China (urban) is expected to have the highest number of diagnosed prevalent cases, increasing from 3.1 million cases in 2018 to 4.1 million cases in 2028. There were 2.8 million cases in India while Australia had 0.08 million diagnosed prevalent cases in 2018. The major drivers for the upward trend in the diagnosed prevalent cases of Axial Spondyloarthritis (AxSpA) in the 5GM (Australia, China [urban], India, South Korea and Japan) over the next decade is partly attributable to aging population combined with the increasing trend in the prevalence of the condition.

The latest report, "Axial Spondyloarthritis: Epidemiology Forecast in Asia-Pacific Markets to 2028", provides an overview of the risk factors and historical trends for Axial Spondyloarthritis across the 5GM (Australia, China [urban], India, South Korea and Japan) in the ages ≥18 years.

Scope

  • Overview of axSpA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized axSpA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the axSpA therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the Asia-Pacific axSpA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Asia-Pacific axSpA therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Asia-Pacific axSpA therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the Asia-Pacific axSpA therapeutics market from 2018-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Axial Spondyloarthritis: Executive Summary

  • 2.1 Axial Spondyloarthritis Market to Experience Mild Growth from 2018-2028
  • 2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves
  • 2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period
  • 2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Axial Spondyloarthritis Pipeline
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario
    • 5.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA - Base Scenario
    • 5.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario
    • 5.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA - Alternative Scenario
    • 5.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients
  • 5.5 Epidemiological Forecast for AS and Nr-axSpA (2018-2028) - Base Scenario
    • 5.5.1 Diagnosed Prevalent Cases of AS
    • 5.5.2 Diagnosed Prevalent Cases of Nr-axSpA
  • 5.6 Epidemiological Forecast for AS and Nr-axSpA (2018-2028) - Alternative Scenario
    • 5.6.1 Diagnosed Prevalent Cases of AS
    • 5.6.2 Age-Specific Diagnosed Prevalent Cases of AS
    • 5.6.3 Sex-Specific Diagnosed Prevalent Cases of AS
    • 5.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity
    • 5.6.5 Diagnosed Prevalent Cases of Nr-axSpA
    • 5.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-axSpA
    • 5.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-axSpA
  • 5.7 Discussion
    • 5.7.1 Epidemiological Forecast Insight
    • 5.7.2 Limitations of the Analysis
    • 5.7.3 Strengths of the Analysis

6 Disease Management in APAC

  • 6.1 Diagnosis and Treatment Overview
  • 6.2 India
  • 6.3 China
  • 6.4 Australia
  • 6.5 South Korea
  • 6.6 Japan

7 Competitive Assessment

8 Unmet Needs and Opportunity Assessment in APAC

10 Current and Future Players in APAC

11 APAC Markets

12 Appendix